NCT07177469

UBT251 Injection Phase II Study (Overweight or Obesity)

A Phase II Study to Evaluate the Efficacy and Safety of UBT251 Injection in Overweight/Obese Patients

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 205 (actual)
• Sponsor: The United Bio-Technology (Hengqin) Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This randomized, double-blind, parallel, placebo-controlled phase II study to evaluate the efficacy and safety of UBT251 Injection in overweight/obese patients

Conditions

• Obesity &Amp; Overweight

Interventions

Type	Name	Description
DRUG	UBT251 Injection 2.0 mg and UBT251 Injection Placebo	UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly
DRUG	UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo	UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly
DRUG	UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo	UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly
DRUG	UBT251 Injection 6.0 mg and UBT251 Injection Placebo	UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly

Timeline

• Start date: 2025-03-10
• Primary completion: 2025-12-30
• Completion: 2025-12-30
• First posted: 2025-09-17
• Last updated: 2025-09-17

Locations

1 site across 1 country: China